ARTICLE | Financial News
How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class
May 23, 2019 5:02 PM UTC
A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after becoming the third biopharma this month to price its offering below its anticipated range.
Bicyclic peptides developer Bicycle Therapeutics plc (NASDAQ:BCYC) raised $60.7 million through the sale of 4.3 million ADSs at $14, the low end of its $14-$16 range, giving it a valuation of $247.7 million...